Reuters Photojournalism
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more | Photo caption
Message of humility
A religious fraternity in Rio considers the election of Pope Francis, a confirmation of their beliefs in poverty and simplicity. Slideshow
Sponsored Links
Pfizer to buy maker of attention-deficit drug for $255 million
The entrance of Pfizer World headquaters in New York City, August 31, 2003. ECONM
Credit: Reuters/Jeff Christensen JC
(Reuters) - Pfizer Inc said it would buy privately held-NextWave Pharmaceuticals for $255 million, gaining access to the company's attention deficit hyperactivity disorder drug, the first once-daily liquid medicine approved to treat the condition in the United States.
NextWave's shareholders would also be eligible to get up to $425 million based on certain sales milestones.
Pfizer said it was exercising its option to acquire NextWave under an agreement signed in the second quarter, under which it had made an option payment of $20 million.
The drug, Quillivant XR, is expected to be available in pharmacies by early next year.
(Reporting by Zeba Siddiqui in Bangalore; Editing by Sreejiraj Eluvangal)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters